131 related articles for article (PubMed ID: 2378546)
1. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
Van Putten T; Marder SR; Mintz J
Arch Gen Psychiatry; 1990 Aug; 47(8):754-8. PubMed ID: 2378546
[TBL] [Abstract][Full Text] [Related]
2. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
3. Dosage of haloperidol for schizophrenia.
Rifkin A; Doddi S; Karajgi B; Borenstein M; Wachspress M
Arch Gen Psychiatry; 1991 Feb; 48(2):166-70. PubMed ID: 1989572
[TBL] [Abstract][Full Text] [Related]
4. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
5. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.
Patris M; Agussol P; Alby JM; Brion S; Burnat G; Castelnau D; Deluermoz S; Dufour H; Ferreri M; Goudemand M
Acta Psychiatr Scand Suppl; 1990; 358():78-82. PubMed ID: 1978497
[TBL] [Abstract][Full Text] [Related]
6. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Alphs LD; Lee HS
J Clin Psychiatry; 1991 Aug; 52(8):346-8. PubMed ID: 1869497
[TBL] [Abstract][Full Text] [Related]
7. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T; Marder SR; Mintz J; Poland RE
Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
[TBL] [Abstract][Full Text] [Related]
9. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
10. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
11. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
12. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Peuskens J
Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
[TBL] [Abstract][Full Text] [Related]
13. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
15. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
16. An open trial of buspirone added to neuroleptics in schizophrenic patients.
Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol plasma levels and dose optimization.
Coryell W; Miller DD; Perry PJ
Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
[TBL] [Abstract][Full Text] [Related]
18. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
19. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
20. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
